In the US,<unk>  is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult crohn's disease, pediatric crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. In the EU it is indicated for the treatment of: * plaque psoriasis (a disease causing red, scaly patches on the skin); * psoriatic arthritis (a disease causing red, scaly patches on the skin with inflammation of the joints); * rheumatoid arthritis (a disease causing inflammation of the joints); * axial spondyloarthritis (inflammation of the spine causing back pain), including ankylosing spondylitis and when X-ray does not show disease but there are clear signs of inflammation; * polyarticular juvenile idiopathic arthritis and active enthesitis-related arthritis (both rare diseases causing inflammation in the joints); * Crohn's disease (a disease causing inflammation of the gut); * ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut); * hidradenitis suppurativa (acne inversa), a long-term skin disease that causes lumps, abscesses (collections of pus) and scarring on the skin; * non-infectious uveitis (inflammation of the layer beneath the white of the eyeball). * chronic cases of aggressive progressive pulmonary and bone sarcoidosis. Rheumatoid arthritis<unk>  has been shown to reduce the signs and symptoms of moderate to severe rheumatoid arthritis in adults. It may be used alone or in combination with disease-modifying antirheumatic drugs (DMARD). It has also been shown to have efficacy in moderate to severe polyarticular juvenile idiopathic arthritis in children four years and older, and is indicated for the treatment of that condition. In rheumatoid arthritis, it is indicated for use alone, or with methotrexate or similar medicines, in the United States since 2002. It has a similar effectiveness as methotrexate and, in combination, nearly doubles the response rate of methotrexate alone. Ankylosing spondylitis<unk>  has been shown to reduce the signs and symptoms of, and is approved for treatment of, ankylosing spondylitis in adults. Crohn's disease<unk>  has been shown to reduce the signs and symptoms of moderate to severe Crohn's disease. It has been approved for that use in the UK since 2009. Ulcerative colitis<unk>  may be effective and well tolerated in ulcerative colitis. It was approved by the US Food and Drug Administration (FDA) for treatment of moderate to severe cases in adults. Plaque psoriasis<unk>  has been shown to treat moderate to severe chronic plaque psoriasis in adults who have the condition in many areas of their body and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).<unk>  has been shown to be effective therapy when used either continuously or intermittently in patients with moderate to severe psoriasis. Hidradenitis suppurativa<unk>  was approved for hidradenitis suppurativa in 2015. Juvenile idiopathic arthritis<unk>  has been shown to reduce the signs and symptoms of moderate to severe polyarticular juvenile idiopathic arthritis in children aged four years and older. Non-infectious uveitis<unk>  is indicated for the treatment of non-infectious uveitis (inflammation of the layer beneath the white of the eyeball).
Adalimumab
Etanercept
Belatacept
Abatacept
Tofacitinib
Sarilumab
Rituximab
Ruxolitinib